1. Differences in integrated assessment and management of non-communicable diseases (NCDs) for people with HIV across the WHO European region. Kraef C, Singh S, Fursa O, Abutidze A, Rukhadze N, Mulabdic V, Yancheva N, Mehmeti M, Balayan T, Harxhi A, Trajanovska J, Mackintosh C, Duvivier C, Beniowski M, Jilich D, Reikvam DH, Tau L, Podlekareva D, Ryom L, Peters L, Kowalska J, Kirk O; EuroSIDA Study Group.
   HIV Med. 2024. Epub ahead of print. Abstract
    
2. SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort. Fursa O, Bannister W, Neesgaard B, Podlekareva D, Kowalska J, Benfield T, Gerstoft J, Reekie J, Rasmussen LD, Aho I, Guaraldi G, Staub T, Miro JM, Laporte JM, Elbirt D, Trofimova T, Sedlacek D, Matulionyte R, Oprea C, Bernasconi E, Hadžiosmanović V, Mocroft A, Peters L; EuroSIDA Study Group.
   HIV Med. 2024. Epub ahead of print. Abstract
    

IN PRESS

1. Association between change in body mass index and risk of hypertension and dyslipidemia in people receiving integrase inhibitors and/or tenofovir alafenamide compared to other contemporary antiretroviral regimens: Byonanebye DM, Polizzotto MN, Maltez F, Rauch A, Pfistershammer KG, Wit F, De Wit S, Castagna A, Monforte AD, Mussini C, Wasmuth JC, Fontas E, Abela I, Sarcletti M, Matharu LB, Jaschinski N, Peters L, Hosein SR, Vannappagari V, Cohen C, Bissio E, Mocroft A, Law M, Ryom L, Petoumenos L. The RESPOND consortium of prospective cohorts. Published in Lancet HIV